close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

296.30 -2.13 (-0.71%)
Official Closing Price Updated: 4:15 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
59 60 Next >
3 Dividend Stocks Crushing the S&P 500 With 30%+ Annual Total Returns
With technology growth stocks propelling the S&P 500, dividend stocks have often found themselves playing catch-up. But not these three. 
Via InvestorPlace
Topics Stocks
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... 
Via Talk Markets
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
What the Options Market Tells Us About Amgen
 
Via Benzinga
Amgen Unusual Options Activity
 
Via Benzinga
Can Amgen Stock Keep Trouncing the S&P 500?
Amgen's market-beating ways are unlikely to evaporate any time soon. 
Via The Motley Fool
Topics Stocks
Amgen, Inc. Dividend Stock Analysis
Amgen Inc. is one of the world's leading biotech companies with major treatments for anemia, neutropenia, rheumatoid and psoriatic arthritis, psoriasis, cancer and osteoporosis. 
Via Talk Markets
The 3 Best Healthcare Stocks to Buy in July 2024
Consistent breakthroughs, improved products and relatively consistent growth make these the best healthcare stocks to buy. 
Via InvestorPlace
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Eli Lilly is a good stock to buy, but these should be even better. 
Via The Motley Fool
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector... 
Via Benzinga
Topics Economy Stocks
Smart Money Is Betting Big In AMGN Options
 
Via Benzinga
Where Will Amgen Be in 5 Years?
Can Amgen be a market-beating stock? 
Via The Motley Fool
Check Out What Whales Are Doing With AMGN
 
Via Benzinga
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
1 Dividend Growth Stock to Buy and Hold for 10 Years
This company's payouts look safe. 
Via The Motley Fool
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends
A look at 10 blue-chip dividend growth stocks with yields above 3%, the opportunity for those yields to continue growing in the future, and where we can be very certain that the dividend is safe. 
Via Talk Markets
These Are The Best Dow Jones Stocks Of 2024 Thus Far
The AI boom helped to produce two best Dow Jones stocks, including newbie Amazon. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Expert Ratings For Amgen
 
Via Benzinga
Decoding Amgen's Options Activity: What's the Big Picture?
 
Via Benzinga
Tech Is Consolidating And The Market’s Seeking New Leadership
The tape tells the tale, just like it always does: The tech sector is clearly in consolidation mode right now. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily
3 Stocks to Buy as Ozempic Surges in Popularity
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand. 
Via InvestorPlace
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Enthusiasm is growing for a looming approval in COPD treatment. 
Via Investor's Business Daily
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today